Fertility Preservation for Transgender Individuals: What to Know Before Starting Hormone Therapy

Gender-affirming hormone therapy (GAHT) is life-changing for many transgender and gender-diverse (TGD) people, but it may permanently affect fertility. Leading 2026 clinical guidelines from ASRM, WPATH and the Endocrine Society all stress one key recommendation: fertility preservation counselling should happen before starting GAHT.

This article breaks down preservation choices, the critical pre-GAHT time window, and important talking points for your appointment with your reproductive provider.

Why Consider Fertility Preservation Before Hormone Therapy?

Gender-affirming hormone therapy works by introducing testosterone or estrogen to align physical characteristics with a person’s gender identity. These hormonal shifts exert direct effects on reproductive function.

For transmasculine individuals (assigned female at birth, AFAB), testosterone therapy suppresses ovarian function, which can stop ovulation and menstruation. Testosterone alters follicular development and oocyte maturation.

While some effects may reverse after stopping GAHT, long-term reproductive impacts are still not fully understood.

For transfeminine individuals (assigned male at birth, AMAB), estrogen plus anti-androgen therapy suppresses spermatogenesis. This may lower sperm count, reduce motility, and in some cases lead to azoospermia (no sperm detectable in ejaculate).

Key takeaway: The optimal time for fertility preservation is before starting hormone therapy. Once GAHT commences, the quantity and quality of reproductive cells may decline, lowering preservation success rates.

What Are the Fertility Preservation Options?

ASRM 2026 guidelines cover a spectrum of fertility-preservation approaches. The best option depends on your anatomy, age, and personal priorities.

1. Sperm Cryopreservation

If you were assigned male at birth (AMAB), the primary established method is sperm cryopreservation.

Sperm cryopreservation is the most mature, widely accessible fertility-preservation option for transfeminine people. The process is straightforward. You provide a semen sample, which is processed, mixed with cryoprotectants, and stored long-term in liquid nitrogen.

For people unable to produce an ejaculated semen sample, including prepubertal adolescents or those with specific medical conditions, surgical testicular sperm extraction (TESE) may be considered.

Important note: Even after starting GAHT, a temporary treatment pause may, in select cases, allow sperm production to recover before banking.

2. Egg Freezing or Embryo Cryopreservation

If you were assigned female at birth (AFAB), main options are oocyte cryopreservation (egg freezing) or embryo cryopreservation.

Egg freezing is more complex compared to sperm cryopreservation. It involves ovarian stimulation with injectable fertility medications, oocyte-retrieval minor surgery, followed by laboratory cryopreservation; the full cycle typically spans 2-3 weeks.

Embryo freezing involves fertilizing retrieved oocytes with sperm, then cryopreserving resulting embryos for future use. This can be a valuable route for transmasculine individuals in stable partnerships.

For prepubertal people who cannot yet produce mature gametes: ovarian-tissue cryopreservation or testicular-tissue cryopreservation may be discussed. 

Ovarian tissue cryopreservation has more than 180 reported live-birth cases globally. Testicular tissue cryopreservation for prepubertal AMAB patients remains entirely experimental.

Important note: Even with prior testosterone use, some transmasculine patients can still undergo ovarian stimulation to obtain viable oocytes, though outcomes differ widely from person to person.

What Does the Fertility Preservation Process Involve?

Fertility-preservation care generally follows these core steps:

3. Consultation & clinical evaluation

Meet with a reproductive-medicine specialist to review options, expected success rates, and associated costs. ASRM guidance stresses the need for respectful, culturally competent care for transgender patients.

4. Psychological support and informed consent

ASRM advises dedicated mental-health clinical assessment prior to undertaking fertility-preservation decision-making, given the weight of future family-building choices.

5. FDA-mandated infectious-disease screening

Gamete cryopreservation requires infectious‑disease screening under US FDA rules.

This requirement chiefly applies to gametes intended for third-party use; screening rules for private self-only storage differ across countries and laboratories. This screening will shape your later options for transfer reproduction.

6. Preservation procedure

Depending on your plan: sperm cryopreservation, oocyte retrieval & freezing, embryo cryopreservation, or experimental tissue-cryopreservation procedures.

7. Long-term cryostorage

Frozen gametes or reproductive tissue can be held in liquid-nitrogen storage for many years for future use.

What If Hormone Therapy Has Already Started?

Fertility preservation may still be achievable after starting GAHT, yet this always calls for personalized clinical assessment.

1. For transfeminine individuals: Some data suggest pausing estrogen + anti-androgen GAHT for 3-6 months may partially restore spermatogenesis for certain patients.

Still, cumulative GAHT exposure correlates with trends toward poorer sperm quality. Preserving before hormone initiation delivers more favourable odds.

2. For transmasculine individuals: Clinical reports show ovarian stimulation can yield mature oocytes even after testosterone treatment. A study found no difference in mature oocyte yield with prior testosterone exposure, but blastocyst counts may be impacted. There is wide patient-to-patient variability, so specialist evaluation is mandatory.

What Barriers Exist to Fertility Preservation?

Even with unified international clinical recommendations for pre-GAHT fertility-preservation counselling, real-world uptake by transgender and gender-diverse people stays comparatively low.

Key barriers include:

1. Financial burden: Fertility-preservation services are frequently self-pay and carry substantial costs;

2. Information gaps: Many TGD people are unaware of GAHT’s fertility impacts or available preservation pathways;

3. System-level healthcare barriers: Not all clinics have training delivering inclusive transgender-competent re productive care;

4. Unique hurdles for prepubertal / adolescent people: Conventional gamete collection is impossible before puberty arrives.

The Bottom Line

Fertility preservation represents a critical consideration for transgender and gender-diverse people planning gender-affirming hormone therapy.

ASRM, WPATH and the Endocrine Society all explicitly recommend fertility-preservation counselling before starting GAHT.

It may still be possible to pursue preservation after starting hormone therapy, though success prospects may be reduced.

If you are considering gender-affirming hormone therapy, it is never too early to discuss fertility-preservation possibilities. Consulting an inclusive reproductive-medicine specialist is the starting point for building your personalised plan.

Have questions about fertility-preservation pathways? Connect with the CEF fertility team. Email info@cefivf.com or visit our Contact page.

Disclaimer: This educational article draws on 2026 ASRM committee opinions, NICE clinical guidance, and peer-reviewed reproductive-health research.

This content is not personalised medical advice. Always consult a licensed, culturally-competent reproductive-endocrinology provider for your individual care decisions.